LENZ Therapeutics (LENZ) Share-based Compensation (2020 - 2026)
LENZ Therapeutics (LENZ) posted quarterly Share-based Compensation of $4.3 million for Q1 2026, up 69.04% year-over-year from $2.6 million in Q1 2025, and up 269.04% quarter-over-quarter from -$2.6 million in Q2 2025.
LENZ Therapeutics (LENZ) Share-based Compensation (2020 - 2026) Analysis & Trends
LENZ Therapeutics (LENZ) has reported Share-based Compensation for 7 consecutive years, with $4.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation rose 69.04% year-over-year to $4.3 million; the TTM figure through Mar 2026 stood at $1.8 million (down 35.24% YoY), while the FY2024 annual figure was $1.1 million, down 84.92% from the prior year.
- Share-based Compensation improved to $4.3 million in Q1 2026 per LENZ's latest filing, from -$2.6 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $9.9 million in Q3 2023 and bottomed at -$3.6 million in Q4 2024.
- Historically, Share-based Compensation has averaged $2.4 million across 5 years, with a median of $3.2 million in 2022.
- Annual changes were most pronounced in 2022 — Share-based Compensation soared 223.52% — and 2025, when it slumped 1042.8%.
- LENZ Therapeutics' Share-based Compensation stood at $3.6 million in 2022, then surged by 173.33% to $9.9 million in 2023, then tumbled by 136.56% to -$3.6 million in 2024, then gained by 29.4% to -$2.6 million in 2025, then surged by 269.04% to $4.3 million in 2026.
- Business Quant data shows LENZ's Share-based Compensation at $4.3 million in Q1 2026, -$2.6 million in Q2 2025, and $2.6 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | LENZ Therapeutics | 146.20 Mn | 146.20 Mn | 5.21 Mn | 4.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.47 Mn |
| Jun 30, 2026 | 4.47 Mn |
| Mar 31, 2026 | 4.32 Mn |
| Mar 31, 2026 | 4.32 Mn |
| Jun 30, 2025 | -2.56 Mn |
| Jun 30, 2025 | -2.56 Mn |
| Mar 31, 2025 | 2.56 Mn |
| Mar 31, 2025 | 2.56 Mn |
| Dec 31, 2024 | -3.62 Mn |
| Dec 31, 2024 | -3.62 Mn |
| Sep 30, 2024 | 3.52 Mn |
| Sep 30, 2024 | 3.52 Mn |
| Jun 30, 2024 | 271,000.00 |
| Jun 30, 2024 | 271,000.00 |
| Mar 31, 2024 | 947,000.00 |
| Mar 31, 2024 | 947,000.00 |
| Sep 30, 2023 | 9.90 Mn |
| Sep 30, 2023 | 9.90 Mn |
| Jun 30, 2023 | 2.85 Mn |
| Jun 30, 2023 | 2.85 Mn |